Search

The article discusses the approval of U.S. Food and Drug Administration (FDA) on the new drugs which predicts clinical benefits. Topics mention including the drug manufacturers who commits on conducting a postapproval trials which confirms the efficacy of drugs, revision of drug labelling and several drugs which are selected and have received the accelerated approval since 2011 with their cost.

The article offers information on the 21st Century Cures Act which was approved by the U.S. House of Representatives. Topics include the bill's ability to push for the development of new drugs, possible increases in the budget of the National Institutes of Health (NIH), and the establishment of the NIH Innovation Fund. It also discusses the need for the faster approval for new drugs, the involvement of the Food and Drug Administration (FDA), and the use of adaptive trial designs.

Letters to the editor are presented in response to the article about the drug development programs of the U.S. Food and Drug Administraton (FDA) and its implications for patients, which appeared in the March 27, 2014 issue.